{
    "name": "chenodiol",
    "comment": "Rx",
    "other_names": [
        "Chenodal"
    ],
    "classes": [
        "Gallstone Solubilizing Agents"
    ],
    "source": "https://reference.medscape.com/drug/chenodal-chenodiol-342065",
    "pregnancy": {
        "common": [
            "Pregnancy Category: X",
            "Lactation: unknown whether cevimeline is distributed into breast milk, avoid using in nursing women"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: unknown whether cevimeline is distributed into breast milk, avoid using in nursing women"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Not an appropriate treatment for many patients with gallstones because of potential hepatotoxicity, poor response rate in some patient subgroups, and increased rate of cholecystectomy in other subgroups",
                "Reserve for carefully selected patients",
                "Treatment must include systematic monitoring for liver function alterations"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Gallstone complication requiring surgery",
                "Known hepatocyte or bile ductal abnormalities, inflammatory bowel disease",
                "Pregnancy"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Orphan drug status, for use in surgical high-risk patients with radiolucent stones",
                "Breastfeeding",
                "Concomitant use with clofibrate",
                "Hepatotoxicity",
                "Dose related diarrhea occurs",
                "50% of cases have stone recurrence in 5 yr"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aluminum hydroxide",
            "description": {
                "common": "aluminum hydroxide decreases levels of chenodiol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "calcium carbonate decreases levels of chenodiol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crofelemer",
            "description": {
                "common": "crofelemer increases levels of chenodiol by Other (see comment). Use Caution/Monitor. \nComment: Crofelemer has the potential to inhibit transporters MRP2 and OATP1A2 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eluxadoline",
            "description": {
                "common": "eluxadoline increases levels of chenodiol by decreasing metabolism. Use Caution/Monitor. Eluxadoline may increase the systemic exposure of coadministered OATP1B1 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium bicarbonate",
            "description": {
                "common": "sodium bicarbonate decreases levels of chenodiol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium citrate/citric acid",
            "description": {
                "common": "sodium citrate/citric acid decreases levels of chenodiol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "chenodiol increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cholestyramine",
            "description": {
                "common": "cholestyramine decreases levels of chenodiol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "colesevelam",
            "description": {
                "common": "colesevelam decreases levels of chenodiol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "colestipol",
            "description": {
                "common": "colestipol decreases levels of chenodiol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "30-40"
        },
        {
            "name": "Biliary pain",
            "percent": "10-15"
        },
        {
            "name": "Increased aminotransferase",
            "percent": "30"
        },
        {
            "name": "Abdominal cramps",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Heartburn",
            "percent": null
        },
        {
            "name": "Flatulence",
            "percent": null
        },
        {
            "name": "Increased LFT",
            "percent": null
        },
        {
            "name": "s",
            "percent": null
        },
        {
            "name": "Increased LDL and total cholesterol",
            "percent": null
        }
    ]
}